In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 10mg Cypress Compound Co Hims & Hers stock rises as FDA schedules peptide review In the era of Make America Healthy Again, the popularity of peptidesshort chains of amino acids that often act as signalling molecules in the bodyhas risen sharply. Many compounding pharmacies, which produce